Advertisement

Diabetologia

, Volume 34, Issue 6, pp 429–434 | Cite as

Follow-up of cyclosporin A treatment in Type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects

  • S. Martin
  • G. Schernthaner
  • J. Nerup
  • F. A. Gries
  • V. A. Koivisto
  • J. Dupré
  • E. Standl
  • P. Hamet
  • R. McArthur
  • M. H. Tan
  • K. Dawson
  • A. E. Mehta
  • S. Van Vliet
  • B. von Graffenried
  • C. Stiller
  • H. Kolb
Originals

Summary

In the Canadian/European randomized controlled study on cyclosporin A (CsA) in recent onset Type 1 (insulin-dependent) diabetes, treatment with the immunosuppressive drug had increased and maintained Beta-cell function and clinical remission during the first 12 months. Following discontinuation of the study drug and double-blinding after a mean of 13.8 months former CsA patients doubled the daily insulin dose within 6 months reaching the level of former placebo patients. The difference in Beta-cell function between the two groups was also lost. Metabolic control (HbA1c) was transiently worse in the former CsA group. Adverse effects of cyclosporin A on systolic blood pressure, haemoglobin levels, serum potassium and creatinine levels also remitted during that time. We conclude that treatment with cyclosporin A for a mean of 13.8 months had no long-lasting effect on the course of Type 1 diabetes persisting beyond drug discontinuation.

Key words

Cyclosporin A Type 1 (insulin-dependent) diabetes mellitus immunotherapy C-peptide islet function remission of Type 1 diabetes 

References

  1. 1.
    Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, von Graffenried B, Wolfe BMJ (1984) Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362–1367PubMedGoogle Scholar
  2. 2.
    Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P Du Rostu H, Rodier M, Sirmai J, Lallemand A, Bach JF (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Lancet II: 119–123CrossRefGoogle Scholar
  3. 3.
    The Canadian/European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37: 1574–1582Google Scholar
  4. 4.
    Dupré J, Stiller CR, Gent M, Donner A, von Graffenried B, Murphy G, Heinrichs D, Jenner MR, Keown PA, Laupacis A, Mahon J, Martell R, Rodger NW, Wolfe BW (1988) Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: The Canadian open study at 44 months. Transpl Proc XX [Suppl 4]: 184–192Google Scholar
  5. 5.
    Assan R, Feutren G, Sirmai J (1988) Cyclosporine trials in diabetes: updated results of the French experience. Transpl Proc XX [Suppl 4]: 178–183Google Scholar
  6. 6.
    Dupré J, Stiller CR, Gent M, Donner A, von Graffenried B, Heinrichs D, Jenner M, Keown P, Mahon J, Martell R, Momah CI, Murphy G, Rodger NW, Wolfe BM (1988) Clinical trials of cyclosporin in IDDM. Diabetes Care 11 [Suppl 1]: 37–44PubMedGoogle Scholar
  7. 7.
    Andreani D, Kolb H, Pozzilli P (1989) Immunotherapy of type 1 diabetes. John Wiley & Sons, ChichesterGoogle Scholar
  8. 8.
    Like AA, Dirodi V, Thomas S, Guberski DL, Rossini AA (1984) Prevention of diabetes mellitus in the BB/W rat with cyclosporin-A. Am J Pathol 117: 92–97PubMedGoogle Scholar
  9. 9.
    Brayman KL, Armstrong J, Barker CF, Naji A (1986) Intermittent cyclosporine administration and prevention of diabetes in the BB rat. Transpl Proc XVIII: 1545–1547Google Scholar
  10. 10.
    Jaworski MA, Jewell LD, Honore L, Metha JG, Bayens-Simmonds J, McGuire-Clark P, Schouls JJ, Yap WY (1987) Immunosuppression in autoimmune disease: the double-edged sword in BB rat. Clin Invest Med 10: 488–495PubMedGoogle Scholar
  11. 11.
    Vague P, Vialettes B, Picq R, Dol S, Lassmann-Vague V (1989) Effect of cyclosporin A on B-cell loss in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32: 887–888 (Letter)CrossRefPubMedGoogle Scholar
  12. 12.
    Feldt-Rasmussen B, Jensen T, Dieperink H, Mandrup-Poulsen T, Nerup J, Bendtzen K, Andersen V, Kemp E, Leyssac PP (1990) Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus. Diab Med 7: 429–433Google Scholar
  13. 13.
    Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF (1988) Factors associated with early remission of type 1 diabetes in children treated with cyclosporine. N Engl J Med 318: 663–670PubMedGoogle Scholar
  14. 14.
    Feutren G (1988) Functional consequences and risk factors of chronic cyclosporine nephrotoxicity in type 1 diabetes trials. Transpl Proc XX [Suppl 4]: 356–366Google Scholar
  15. 15.
    Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF (1990) Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39: 1264PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • S. Martin
    • 1
  • G. Schernthaner
    • 2
  • J. Nerup
    • 3
  • F. A. Gries
    • 1
  • V. A. Koivisto
    • 4
  • J. Dupré
    • 5
  • E. Standl
    • 6
  • P. Hamet
    • 7
  • R. McArthur
    • 8
  • M. H. Tan
    • 9
  • K. Dawson
    • 10
  • A. E. Mehta
    • 11
  • S. Van Vliet
    • 12
  • B. von Graffenried
    • 13
  • C. Stiller
    • 5
  • H. Kolb
    • 1
  1. 1.Diabetes Research InstituteUniversity of DüsseldorfDüsseldorfFRG
  2. 2.Krankenanstalt RudolfstiftungViennaAustria
  3. 3.Steno Memorial HospitalGentofteDenmark
  4. 4.Second Department of MedicineHelsinki UniversityHelsinkiFinland
  5. 5.University HospitalLondonCanada
  6. 6.Städtisches Krankenhaus München-SchwabingMunichFRG
  7. 7.Clinical Research InstituteMontreal
  8. 8.Alberta Children's HospitalUniversity of CalgaryCalgary
  9. 9.Camp Hill Medical CentreHalifax
  10. 10.University HospitalVancouver
  11. 11.Health Science CentreWinnipeg
  12. 12.University of SaskatchewanSaskatoonCanada
  13. 13.SandozSwitzerland

Personalised recommendations